Home › Urinary Incontinence › NCT04248283
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Recruiting
A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Who can join
Ages 22 and older · Women
Full eligibility criteria
Inclusion Criteria: 1. Female at least 22 years old 2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency 3. Provocative pad weight of greater than 11.0 grams 4. Candidate for surgical intervention 5. Negative urinalysis 6. Normal cystourethroscopy 7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent) 8. Willing and able to sign informed consent and comply with trial follow-up requirements Exclusion Criteria: 1. Pregnant or lactating 2. Life expectancy of less than 5 years 3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL 4. Has auto-immune disease 5. Undergoing radiation therapy 6. Active urinary tract infection 7. Detrusor instability refractory to medication 8. Reduced bladder compliance as defined by a cystometrogram 9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml 10. Has, had, or is suspected of having bladder cancer 11. History of bladder stones 12. Urethral stricture evidenced during cystourethroscopy 13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia 14. Has a diathesis, hemophilia, or a bleeding disorder 15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher 16. Had prior pelvic radiotherapy 17. Had a prior artificial urinary sphincter implanted 18. Has a neurogenic condition known to affect bladder/sphincter function
About the study
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
What is being tested
- Adjustable Continence Therapy for Women (ACT) (device)
Sponsor: Uromedica · Participants: 167 · Started: Jan 26, 2021
Contact the study team
- Lisa Draper · Phone: 612-834-7494
- Matt Kelly, PhD · Phone: 612-469-8882
Official record on ClinicalTrials.gov — NCT04248283
Locations in the U.S.
| Colorado | University of Colorado, Denver |
| Nebraska | CHI Health Research Center, Omaha |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.